BR112014011009A2 - inibidor duplo de met e vegf para tratar câncer - Google Patents

inibidor duplo de met e vegf para tratar câncer

Info

Publication number
BR112014011009A2
BR112014011009A2 BR112014011009A BR112014011009A BR112014011009A2 BR 112014011009 A2 BR112014011009 A2 BR 112014011009A2 BR 112014011009 A BR112014011009 A BR 112014011009A BR 112014011009 A BR112014011009 A BR 112014011009A BR 112014011009 A2 BR112014011009 A2 BR 112014011009A2
Authority
BR
Brazil
Prior art keywords
treat cancer
vegf inhibitor
dual met
met
dual
Prior art date
Application number
BR112014011009A
Other languages
English (en)
Portuguese (pt)
Inventor
Dana T Aftab
Frauke Schimmoller
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of BR112014011009A2 publication Critical patent/BR112014011009A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
BR112014011009A 2011-11-08 2012-11-08 inibidor duplo de met e vegf para tratar câncer BR112014011009A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161557358P 2011-11-08 2011-11-08
PCT/US2012/064116 WO2013070890A1 (en) 2011-11-08 2012-11-08 Dual inhibitor of met and vegf for treating cancer

Publications (1)

Publication Number Publication Date
BR112014011009A2 true BR112014011009A2 (pt) 2017-06-06

Family

ID=47179011

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011009A BR112014011009A2 (pt) 2011-11-08 2012-11-08 inibidor duplo de met e vegf para tratar câncer

Country Status (15)

Country Link
US (1) US20140323522A1 (enExample)
EP (1) EP2776033A1 (enExample)
JP (2) JP2014532766A (enExample)
KR (1) KR20140088610A (enExample)
CN (1) CN104159585A (enExample)
AU (2) AU2012335737A1 (enExample)
BR (1) BR112014011009A2 (enExample)
CA (1) CA2854336A1 (enExample)
EA (1) EA201490944A1 (enExample)
HK (1) HK1202062A1 (enExample)
IL (1) IL232421A0 (enExample)
IN (1) IN2014CN04067A (enExample)
MX (1) MX2014005458A (enExample)
TW (2) TWI662962B (enExample)
WO (1) WO2013070890A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
CA2826751C (en) 2011-02-10 2021-05-18 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
KR20140069133A (ko) 2011-09-22 2014-06-09 엑셀리시스, 인코포레이티드 골다공증의 치료방법
EP2768796B1 (en) 2011-10-20 2019-11-20 Exelixis, Inc. Process for preparing quinoline derivatives
WO2013166296A1 (en) * 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
BR112015023109A2 (pt) 2013-03-15 2018-05-15 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinoloin-4-il] oxi}fenil)-n -(4-fluorofenil)ciclopropano-1, 1- dicarboxamida
WO2014165786A1 (en) 2013-04-04 2014-10-09 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
US9149471B2 (en) * 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
CA2939546C (en) 2014-02-14 2023-01-17 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EA201691850A1 (ru) 2014-03-17 2016-12-30 Экселиксис, Инк. Дозирование составов, содержащих кабозантиниб
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
BR112017002318A2 (pt) 2014-08-05 2018-07-17 Exelixis, Inc. combinações de fármacos para tratar mieloma múltiplo.
CN105503717A (zh) * 2014-09-24 2016-04-20 江苏奥赛康药业股份有限公司 一种苹果酸卡博替尼化合物及其药物组合物
CN109069499A (zh) * 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
CN109496212B (zh) * 2016-10-18 2020-08-14 北京康辰药业股份有限公司 一种喹啉基取代的羧酸化合物或其药学上可接受的盐、其药物组合物及应用
EA039654B1 (ru) 2017-05-26 2022-02-22 Экселиксис, Инк. Кристаллические твердые формы солей n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и методы использования
CA3088200A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
TWI770624B (zh) 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2651730T3 (es) 2003-09-26 2018-01-29 Exelixis, Inc. Moduladores c-Met y métodos de uso
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
UA108618C2 (uk) * 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20140057908A1 (en) * 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
EP2621481B2 (en) * 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases

Also Published As

Publication number Publication date
TW201322981A (zh) 2013-06-16
JP2018048154A (ja) 2018-03-29
US20140323522A1 (en) 2014-10-30
KR20140088610A (ko) 2014-07-10
JP2014532766A (ja) 2014-12-08
CN104159585A (zh) 2014-11-19
AU2017225103A1 (en) 2017-09-28
WO2013070890A1 (en) 2013-05-16
EA201490944A1 (ru) 2014-10-30
AU2012335737A1 (en) 2014-06-05
IL232421A0 (en) 2014-06-30
CA2854336A1 (en) 2013-05-16
MX2014005458A (es) 2015-04-16
TWI662962B (zh) 2019-06-21
EP2776033A1 (en) 2014-09-17
HK1202062A1 (en) 2015-09-18
IN2014CN04067A (enExample) 2015-10-23
TW201818937A (zh) 2018-06-01

Similar Documents

Publication Publication Date Title
BR112014011009A2 (pt) inibidor duplo de met e vegf para tratar câncer
CO6920258A2 (es) Proteínas de función dual para tratar trastornos metabólicos
DK2707030T3 (da) Cancerbehandlinger
PL2739153T3 (pl) Leczenie raka sutka
BR112016010224A2 (pt) combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
EP2663304A4 (en) COMBINATION THERAPY
DK2726510T3 (da) Dobbelt målretning
HUE046667T2 (hu) Rák kombinatív kezelése
EP2864360A4 (en) TARGETED THERAPEUTICS
HUE038391T2 (hu) Bromodomén inhibitorok
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
ES2638522T8 (es) Procedimientos para detectar cáncer
BRPI0914614A2 (pt) 2-arilaminoquinazolinas para tratar doenças proliferativas
EP2726095A4 (en) COMBINATION THERAPY
DK2760886T3 (da) Immunocytokin-kombinationsterapi
FI20115876A0 (fi) Yhdistelmähoito
EP2682082A4 (en) Tampon applicator
BR112014005753A2 (pt) flexor eletromagnético
HRP20182043T8 (hr) Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
BR302013001867S1 (pt) Configuração aplicada em aparelho para reprodução de sons
BR112013008528A2 (pt) métodos para tratar psoríase
IL229081A0 (en) Isoxazolines as therapeutic agents
BR112013028890A2 (pt) composições e métodos para o tratamento de câncer
BR112014000021A2 (pt) terapia direcionada para egfr
BR112012027834A2 (pt) método para produzir macarrão instântaneo e macarrão instântaneo

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2487 DE 04-09-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.